Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 45; no. 1; p. 34
• Main Authors: Anastos, Kathryn, Lu, Dalian, Shi, Qiuhu, Tien, Phyllis C, Kaplan, Robert C, Hessol, Nancy A, Cole, Steven, Vigen, Cheryl, Cohen, Mardge, Young, Mary, Justman, Jessica
• Format: Journal Article
• Language: English
• Published: United States 01.05.2007
• Subjects: Adenine - adverse effects; Adenine - analogs & derivatives; Adenine - therapeutic use; Adult; Alkynes; Anti-HIV Agents - adverse effects; Anti-HIV Agents - therapeutic use; Antiretroviral Therapy, Highly Active - adverse effects; Benzoxazines - adverse effects; Benzoxazines - therapeutic use; Black or African American; Black People - statistics & numerical data; Cholesterol - blood; Cross-Sectional Studies; Cyclopropanes; Didanosine - adverse effects; Didanosine - therapeutic use; Dideoxynucleosides - adverse effects; Dideoxynucleosides - therapeutic use; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino - statistics & numerical data; HIV Infections - drug therapy; HIV Infections - metabolism; HIV Protease Inhibitors - adverse effects; HIV Protease Inhibitors - therapeutic use; HIV Seronegativity; HIV Seropositivity - drug therapy; HIV-1; Humans; Indinavir - adverse effects; Indinavir - therapeutic use; Lamivudine - adverse effects; Lamivudine - therapeutic use; Lipids - blood; Lipoproteins, HDL - blood; Lipoproteins, LDL - blood; Multivariate Analysis; Nelfinavir - adverse effects; Nelfinavir - therapeutic use; Nevirapine - adverse effects; Nevirapine - therapeutic use; Organophosphonates - adverse effects; Organophosphonates - therapeutic use; Ritonavir - adverse effects; Ritonavir - therapeutic use; Stavudine - adverse effects; Stavudine - therapeutic use; Tenofovir; Triglycerides - blood; United States; White People - statistics & numerical data; United States
• ISSN: 1525-4135
• DOI: 10.1097/QAI.0b013e318042d5fe

The effects of HIV infection, highly active antiretroviral therapy (HAART), and specific antiretroviral agents on lipoproteins in women are not well described. In a cross-sectional substudy of the Women's Interagency HIV Study with 623 HIV-negative and 1556 HIV-positive women (636 untreated, 419 on non-protease inhibitor [PI] HAART, and 501 on PI-containing HAART), we performed multivariate analyses of associations among fasting lipoprotein levels, HIV infection, and HAART. Untreated HIV-positive women had lower high-density lipoprotein cholesterol (HDL-C) and higher triglycerides (TGs) but not lower low-density lipoprotein cholesterol (LDL-C) than HIV-negative women and were the most likely to have unfavorable HDL-C by National Cholesterol Education Program (NCEP) guidelines. PI HAART users had higher LDL-C than untreated HIV-infected women (107 vs. 100 mg/dL, P = 0.0006) and were the most likely to have unfavorable LDL-C and TGs by NCEP guidelines. HIV-negative women and non-PI HAART users had similar HDL-C levels (55 and 53 mg/dL, respectively), which were higher than those in untreated HIV-infected women and PI HAART users (42 and 49 mg/dL, respectively; P < 0.001 for all). Lamivudine, didanosine, nevirapine, and efavirenz were independently associated with higher HDL-C (P < 0.001 for all). Ritonavir, indinavir/ritonavir, and nelfinavir were associated with higher LDL-C (P < 0.01 for all). Stavudine, abacavir, and all ritonavir-containing regimens were associated with higher TGs (P < 0.05 for all), and tenofovir was associated with lower TGs (P = 0.009). A dyslipidemic pattern was associated with HIV infection itself, was more severe in users of PI-containing HAART, but was not present in women taking non-PI HAART.